TGFB1 and pancreatic neoplasm: Here, we demonstrated a completely opposite outcome of IL-6 targeting, as impairing IL-6 signaling in the TME with an IL-6R blocking antibody abolished the antitumor activity of the TGFβ vaccine in a murine model of pancreatic cancer.